Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Form 4 filing – Inhibikase Therapeutics, Inc. (IKT)
On 06/30/2025, director Dennis N. Berman received 108,176 stock options with an exercise price of $1.95 per share. The grant vests on the earlier of 06/30/2026 or the day prior to the company’s next annual shareholder meeting, subject to continued board service, and expires on 06/30/2032. No common shares were bought or sold in this filing; the reporting person’s beneficial ownership now includes the newly issued options, held directly.